These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 16052941)

  • 41. [Carcinoid syndrome. II. Clinical manifestations, diagnosis, prognosis and treatment].
    Díaz Recasens J; Ruíz Palomo F; Pérez Corral F; Rapado A
    Rev Clin Esp; 1974 Jan; 132(2):91-8. PubMed ID: 4840233
    [No Abstract]   [Full Text] [Related]  

  • 42. A stepwise approach to the management of metastatic midgut carcinoid tumor.
    Bhattacharyya S; Gujral DM; Toumpanakis C; Dreyfus G; Davidson BR; Davar J; Caplin ME
    Nat Rev Clin Oncol; 2009 Jul; 6(7):429-33. PubMed ID: 19561636
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Climacteric flushing in a patient with carcinoid tumour.
    Wilkin JK
    Br J Dermatol; 1985 Mar; 112(3):357-61. PubMed ID: 3978040
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [A neural-endocrine enteropathy].
    Benda L
    Wien Z Inn Med; 1967; 48(9):335-8. PubMed ID: 5620788
    [No Abstract]   [Full Text] [Related]  

  • 45. The use of chromogranin, synaptophysin and islet amyloid polypeptide as markers for neuroendocrine tumours.
    Stridsberg M
    Ups J Med Sci; 1995; 100(3):169-99. PubMed ID: 8808182
    [No Abstract]   [Full Text] [Related]  

  • 46. Dramatic response of a metastatic carcinoid tumour to a combination of interferon and octreotide.
    Joensuu H; Kätkä K; Kujari H
    Acta Endocrinol (Copenh); 1992 Feb; 126(2):184-5. PubMed ID: 1371898
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhibitory effects of ranitidine on flushing and serum serotonin concentrations in carcinoid syndrome.
    Noppen M; Jacobs A; Van Belle S; Herregodts P; Somers G
    Br Med J (Clin Res Ed); 1988 Mar; 296(6623):682-3. PubMed ID: 3128368
    [No Abstract]   [Full Text] [Related]  

  • 48. Serum and plasma 5-hydroxyindoleacetic acid as an alternative to 24-h urine 5-hydroxyindoleacetic acid measurement.
    Adaway JE; Dobson R; Walsh J; Cuthbertson DJ; Monaghan PJ; Trainer PJ; Valle JW; Keevil BG
    Ann Clin Biochem; 2016 Sep; 53(Pt 5):554-60. PubMed ID: 26438520
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Carcinoid syndrome symposium on treatment modalities for gastrointestinal carcinoid tumours: symposium summary.
    Pasieka JL; McKinnon JG; Kinnear S; Yelle CA; Numerow L; Paterson A; Rorstad O; DiFrancesco LM; McEwan A; Skogseid B
    Can J Surg; 2001 Feb; 44(1):25-32. PubMed ID: 11220795
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Diagnosis and treatment of primary hepatic carcinoid tumor].
    Li T; Qin LX; Pan Q; Pang JZ; Wang L; Sun HC; Ye QH; Fan J; Tang ZY
    Zhonghua Wai Ke Za Zhi; 2007 Oct; 45(19):1335-7. PubMed ID: 18241569
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Radioiodinated metaiodobenzylguanidine in the diagnosis and therapy of carcinoid tumors.
    Khan MU; Morse M; Coleman RE
    Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):441-54. PubMed ID: 19088697
    [TBL] [Abstract][Full Text] [Related]  

  • 52. HPLC-mass spectrometry method for quantitative detection of neuroendocrine tumor markers: vanillylmandelic acid, homovanillic acid and 5-hydroxyindoleacetic acid.
    Lionetto L; Lostia AM; Stigliano A; Cardelli P; Simmaco M
    Clin Chim Acta; 2008 Dec; 398(1-2):53-6. PubMed ID: 18760269
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Malignant pancreatic carcinoid tumour.
    Zarina AL; Hamidah A; Zulkifli SZ; Zulfiqar MA; Jamal R
    Singapore Med J; 2007 Dec; 48(12):e320-2. PubMed ID: 18043827
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Somatostatin inhibits diarrhea in the carcinoid syndrome.
    Dharmsathaphorn K; Sherwin RS; Cataland S; Jaffe B; Dobbins J
    Ann Intern Med; 1980 Jan; 92(1):68-9. PubMed ID: 7350874
    [No Abstract]   [Full Text] [Related]  

  • 55. Carcinoid tumors.
    Raut CP; Kulke MH; Glickman JN; Swanson RS; Ashley SW
    Curr Probl Surg; 2006 Jun; 43(6):383-450. PubMed ID: 16781906
    [No Abstract]   [Full Text] [Related]  

  • 56. Carcinoid syndrome. Medical management.
    Clarke B; Hodgson HJ
    Br J Hosp Med; 1986 Mar; 35(3):146-8, 150, 152. PubMed ID: 3742126
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Growling, flushing, and a 30-pound weight loss.
    Khokhar N
    Hosp Pract (Off Ed); 1985 Sep; 20(9A):64-5. PubMed ID: 2411744
    [No Abstract]   [Full Text] [Related]  

  • 58. Ghost carcinoid in a patient with 120-fold elevated 5-hydroxyindoacetic acid.
    Yu R; Wolin E
    Endocr Pract; 2012; 18(5):803-4. PubMed ID: 23047932
    [No Abstract]   [Full Text] [Related]  

  • 59. Tubulovillous adenoma of the duodenum: a new etiology for flushing and urinary 5-HIAA elevation.
    Betchen SA; Cirigliano M; Furth EE; Broussard D; Grippi M; Lichtenstein GR
    Dig Dis Sci; 1998 Jul; 43(7):1474-81. PubMed ID: 9690381
    [No Abstract]   [Full Text] [Related]  

  • 60. Type 1 and 2 gastric carcinoid tumors: long-term follow-up of the efficacy of treatment with a slow-release somatostatin analogue.
    Manfredi S; Pagenault M; de Lajarte-Thirouard AS; Bretagne JF
    Eur J Gastroenterol Hepatol; 2007 Nov; 19(11):1021-5. PubMed ID: 18049175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.